← Eichor
Condition: Philadelphia Positive Acute Lymphoblastic Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Philadelphia Positive Acute Lymphoblastic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Phil
EARLY_Phase 1 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07074496EWALL-PH OBSERVARTORY 2022
Phase N/A · 23 location(s) · Versailles Hospital · NCT07684131Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
Phase 2 · 85 location(s) · Goethe University · NCT06061094ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07493161Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07250087Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
Phase N/A · 1 location(s) · Group for Research in Adult Acute Lymphoblastic Leukemia · NCT07433400Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+
Phase 1/Phase 2 · 1 location(s) · Novartis Pharmaceuticals · NCT07387926Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom
Phase 2 · 1 location(s) · University of Washington · NCT07224100Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03263572Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acut
Phase 1/Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06308588Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With New
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06220487Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481228A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Phase 3 · 90 location(s) · Ascentage Pharma Group Inc. · NCT06051409A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adole
Phase 2 · 155 location(s) · National Cancer Institute (NCI) · NCT06124157Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymph
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07040982Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04260022Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Phase 3 · 24 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07152041
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.